Outlook Therapeutics

Outlook Therapeutics reported an adjusted net loss of $10.9 million ($0.09 per share) for Q3 2026 versus $15.8 million ($0.44 per share) a year earlier, while the FDA approved LYTENAVA in the US roughly three weeks before the report. The company had $11.2 million in cash at quarter-end and raised about $51.1 million net via a capital raise after the quarter. Management plans to build a US sales and reimbursement team (around 50 new hires) and expects rising SG&A costs; it forecasts $50–75 million in net sales in the first 12 months after launch (Europe 10–15%). The stock fell premarket as investors weighed the costly launch and uncertainties about reimbursement and market uptake. » More on de.investing.com

Outlook Therapeutics will release results for the past quarter on August 14, 2026. Three analysts expect on average earnings per share of -0.080 USD versus -0.550 USD a year earlier and revenue of around 1.0 million USD (previous year 1.5 million, -35.76%). For the current fiscal year estimates are for an average loss per share of -0.473 USD (previous year -1.790 USD) and annual revenue of about 2.9 million USD (previous year 1.4 million). » More on finanzen.net

Outlook Therapeutics is offering 55,555,556 common shares together with up to 55,555,556 warrants at a combined price of $0.99 per share plus warrant. The warrants are immediately exercisable, have an exercise price of $1.10 and a five‑year term; syndicate banks receive an overallotment option for 8,333,333 units. Closing is expected on August 14, 2026, and the gross proceeds of roughly $55 million are intended to support the U.S. commercial launch of LYTENAVA, working capital and general corporate purposes. » More on de.investing.com